The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase

Blood

Volumn 96, Issue 2, 2000, Pages 664-670

  Million, Ryan P ^a   Van Etten, Richard A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; BCR ABL PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; HUMAN; HUMAN CELL; LEUKEMOGENESIS; LYMPHATIC LEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

EID: 0034661522     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.2.664     Document Type: Article

References (43)

1. Van Etten RA. The molecular pathogenesis of the Philadelphia-positive leukemias: implications for diagnosis and therapy. In: Freireich EJ, Kantarjian H, eds. Leukemia: Advances in Treatment and Research. Norwood, MA: Kluwer Academic Publishers; 1993:294-325.
2. Lugo TG, Witte ON. The bcr-abl oncogene transforms rat-1 cells and cooperates with v-myc. Mol Cell Biol. 1989;9:1263-1270.
3. Daley G, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210 bcr/ abl protein. Proc Natl Acad Sci U S A. 1988;85: 9312-9316.
4. McLaughlin J, Chianese E, Witte ON. In vitro transformation of immature hematopoietic cells by the P210 bcr/abl oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci U S A. 1987;84:6558-6562.
5. Sawyers CL. Signal transduction pathways involved in BCR-ABL transformation. Baillieres Clin Haematol. 1997;10:223-231.
6. Sawyers CL, McLaughlin J, Witte ON. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med. 1995;181:307-313.
7. Cortez D, Stoica G, Pierce JH, Pendergast AM. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Oncogene. 1996;13:2589-2594.
8. Pendergast AM, Quilliam LA, Cripe LD, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993;75:175-185.
9. Puil L, Liu J, Gish G, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBOJ. 1994;13:764-773.
10. Cortez D, Kadlec L, Pendergast AM. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol. 1995;15:5531-5541.
11. Goga A, McLaughlin J, Afar DE, Saffran DC, Witte ON. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell. 1995;82:981-988.
12. bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-830.
13. Van Etten RA. Animal models of chronic myelogenous leukemia. In: Talpaz M, Kantarjian H, eds. Medical Management of Chronic Myelogenous Leukemia. New York: Marcel Dekker; 1998:77-101.
14. Li S, Ilaria RL, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med. 1999;189:1399-1412.
15. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood. 1998;92: 3780-3792.
16. Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colory-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood. 1998; 92:3829-3840.
17. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A. 1993;90:8392-8396.
18. BCR/ABL is not required for transformation of hematopoietic factor-dependent cells. Blood. 1995;86:3897-3904.
19. Van Etten RA, Debnath J, Zhou H, Casasnovas JM. Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro. Oncogene. 1995;10: 1977-1988.
20. Okuda K, Golub TG, Gilliland DG, Griffin JD. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene. 1996;13:1147-1152.
21. Mayer BJ, Jackson PK, Baltimore D. High-affinity binding of the noncatalytic SH2 segment of the abl tyrosine kinase to tyrosine-phosphorylated cellular proteins. Proc Natl Acad Sci U S A. 1990; 88:627-631.
22. Van Etten RA, Jackson PK, Baltimore D, Sanders MC. Matsudaira PT, Janmey PA. The C-terminus of the c-Abl tyrosine kinase contains distinct F-and G-actin binding domains with bundling activity. J Cell Biol. 1994;124:325-340.
23. Hawley RG, Lieu FHL, Fong AZC, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1994;1:136-138.
24. Finer MH, Dull TJ, Qin L, Farson D, Roberts M. kat. a high-efficiency retroviral transduction system for primary human T lymphocytes. Blood. 1994;83:43-50.
25. Danos O, Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci U S A. 1988;85:6460-6464.
26. Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J Exp Med. 1991;173:1213-1225.
27. Gurish MF, Pear WS, Stevens RL, et al. Tissue-regulated differentiation and maturation of a v-abl-immortalized mast cell-committed progenitor. Immunity. 1995;3:175-186.
28. Pear WS, Miller J, Xu LW, et al. Murine models for studying the pathogenesis of chronic myelogenous leukemia [abstract]. Blood. 1997;90:393a.
29. Holland GD, Ito K, Kaehler DA, Tonegawa S, Risser R. Thymic targets for Abelson murine leukemia virus are early gamma/delta T lymphocytes. Proc Natl Acad Sci U S A. 1991;88:3700-3704.
30. Ilaria RL, de Aos IE, Roumiantsev S, Varticovski L, Van Etten RA. The SH2 domain of BCR/ABL is required for induction of CML-like disease in mice but not for activation of phosphatidylinositol 3-kinase [abstract]. Blood. 1998;92:92a.
31. Skolnik EY, Lee C-H, Batzer A, et al. The SH2/ SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated RIS1 and Shc: implications for insulin control of ras signalling. EMBO J. 1993;12:1929-1936.
32. Songyang Z, Shoelson SE, McGlade J, et al. Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps.fes, GRB-2, HCP, SHC, Syk, and Vav. Mol Cell Biol. 1994;14:2777-2785.
33. Egan SE, Giddings BW, Brooks MW, Buday L, Sizeland AM, Weinberg RA. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature. 1993;363:45-51.
34. Gishizky ML, Cortez D, Pendergast AM. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation. Proc Natl Acad Sci U S A. 1995;92:10889-10893.
35. Songyang Z, Shoelson SE, Chaudhuri M, et al. SH2 domains recognize specific phosphopeptide sequences. Cell. 1993;72:767-778.
36. Gale NW, Kaplan S, Lowenstein EJ, Schlessinger J, Bar-Sagi D. Grb2 mediates the EGF-dependent activation of guanine nucteotide exchange on Ras. Nature. 1993;363:88-92.
37. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and bcr/abl. Proc Natl Acad Sci U S A. 1990;87:6649-6653.
38. Scott ML, Van Etten RA, Daley GQ, Baltimore D. v-abl causes hematopoietic disease distinct from that caused by bcr-abl. Proc Natl Acad Sci U S A. 1991;88:6506-6510.
39. Elefanty AG, Hariharan IK, Cory S. bcr-abl, the hallmark of chronic myeloid leukemia in man, induces multiple hematopoietic neoplasms in mice. EMBO J. 1990;9:1069-1078.
40. Han X, Wong PMC, Chung S-W. Chronic myeloproliferative disease induced by site-specific integration of Abelson murine leukemia virus-infected hemopoietic stem cells. Proc Natl Acad Sci U S A. 1991;88:10129-10133.
41. Gross AW, Zhang X, Ren R. Bcr-Abl with an SH3 deletion retains the ability to induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy. Mol Cell Biol. 1999;19:6918-6928.
42. Muller AJ, Young JC, Pendergast A, et al. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive leukemias. Mol Cell Biol. 1991;11:1785-1792.
43. Schwaller J, Frantsve J, Aster J, et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myeloid-and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion gene. EMBO J. 1998;17:5321-5333.